UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) November 14, 2012

 

 

Angiotech Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

 

British Columbia

 

000-30334

 

98-0226269

(State or other jurisdiction of
incorporation or organization)

 

(Commission
File Number)

 

(IRS Employer
Identification No.)

 

1618 Station Street

Vancouver, BC, Canada V6A 1B6

(Address of principal executive offices)

 

(604) 221-7676

(Registrant’s telephone number, including area code)

 

 

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o             Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o             Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o             Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o             Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


 

ITEM 2.02.                  RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

 

On November 14, 2012, Angiotech issued a press release relating to its results of operations and financial condition for the third quarter ended September 30, 2012. The full text of Angiotech’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information in Item 2.02 of this Current Report on Form 8-K and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

ITEM 9.01.                  FINANCIAL STATEMENTS AND EXHIBITS.

 

(d)                   Exhibits

 

Exhibit
Number

 

Description

 

 

 

99.1

 

Press Release of Angiotech Pharmaceuticals, Inc. dated November 14, 2012.

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Angiotech Pharmaceuticals, Inc.

 

(Registrant)

 

 

 

Date: November 14, 2012

By:

/s/ JAY DENT

 

 

Jay Dent

 

 

Sr. Vice President, Finance

 

3


 

INDEX TO EXHIBITS

 

Exhibit
Number

 

Description

 

 

 

99.1

 

Press Release of Angiotech Pharmaceuticals, Inc. dated November 14, 2012

 

4

Andean Precious Metals (QX) (USOTC:ANPMF)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Andean Precious Metals (QX) Charts.
Andean Precious Metals (QX) (USOTC:ANPMF)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Andean Precious Metals (QX) Charts.